MESOGLYCAN SODIUM [NP-0327], also known as hexuronyl hexosaminoglycan sulfate or
complex sulfomucopolysaccharides, comprises various naturally-occurring polyanions belonging
to the family of the sulfated glycosaminoglycans (GAGs). It consists of about 50% heparan
sulfate, about 35% dermatan sulfate, about 8% of electropheretically slow-moving heparin and
less than 5% of chondroitin sulfate A/C.
Different GAGs have characteristic electrophoretic migration patterns. In cationic buffers, such
as barium acetate, GAGs are separated into a "slow-moving" component of highly sulfated and
higher molecular weight species and "fast-moving" components of less sulfated and lower
molecular weight species. With barium acetate as the electrolyte heparan sulfate and the slowmoving
heparin-like GAGs are clearly separated from dermatan sulfate and chondroitin sulfate.
References
Liszewski K. Biopharma tackles TSEs. GEN 2000; 20: 48.
Griffin CC, Linhardt RJ, Van Gorp CL, et al. Isolation and characterization of heparan sulfate
from crude porcine intestinal mucosal peptidoglycan heparin. Carbohydrate Research 1995;
276: 183-197.
Forconi S, Battistini N, Guerrini M, Passero SG for the SIAM group. A randomized, ASAcontrolled
trial of mesoglycan in secondary prevention after cerebral ischemic events.
Cerebrovasc Dis 1995; 5:334-41.
Zanolo G, Giachetti C, Mascellani G, Magliocca R, Ferrari G. Pharmacokinetic aspects of
trillium-labeled glycosaminoglycans (mesoglycan). Their absorption in rat and monkey and
tissue distribution in rat. Boll Chim Farm 1984; 123:223-35.
Volpi N. Electrophoresis separation of glycosaminoglycans on nitrocellulose membranes. Anal
Biochem 1986; 240:114-118.
Vittorio A, Messa GL, Frigerio C, Celasco G, Auteri A. Effect of a single dose of Mesoglycan on
the human fibrinolytic system, and the profibrinolytic action of nine daily doses. Int J Tiss Reac
1988; :261-6.
Laurora G, Cesarone MR, De Sanctis MT, Incandela L, Belcaro G. Delayed arterioschlerosis
progression in high risk subjects treated with mesoglycan. Evaluation of intima-media
thickness. J Cardiovasc Surg 1993; 34: 313-8.
Nenci GG, Gresel P, Ferrari G, Santoro L, Gianese F. Treatment of intermittent claudication
with Mesoglycan – a placebo-controlled double-blind study. Thromb Haemost 2001; 86:1181-7.
SULODEXIDE [DX-0363] is a low molecular weight derivative of complex sulfomucopolysaccharides having a mean molecular weight of about 8,000. It comprises about 80% of
heparan sulfate and heparin-like fragments and about 20% of dermatan sulfate fragments.
References
Harenberg J. Review of pharmacokynamics. Pharmcokinetics, and therapeutic properties of
sulodexide. Med Res Rev 1998; 18(1): 1-20.
Ofosu F. Pharmacological actions of sulodexide. Semin Thromb Hemost 1998; 24(2): 127-38.
